Evaluating Patient-Defined Priorities for Female Patients with Bladder Cancer.

Autor:	Vo AX; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Keeter MK; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Tuchman ES; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Meeks JJ; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Morgans AK; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Jazyk:	angličtina
Zdroj:	Bladder cancer (Amsterdam, Netherlands) [Bladder Cancer] 2021 Mar 19; Vol. 7 (1), pp. 53-60. Date of Electronic Publication: 2021 Mar 19 (Print Publication: 2021).
DOI:	10.3233/BLC-200397
Abstrakt:	Background: Although bladder cancer is much more common in men than in women, female patients with bladder cancer present with more locally advanced tumors and have worse disease-specific outcomes than male patients, even after controlling for biological differences. There is a paucity of research regarding the optimal approach to caring for female patients with bladder cancer in ways that maximize patient satisfaction, preferences, and values. Objective: We sought to explore patient-defined priorities and areas in need of improvement for female patients with bladder cancer from the patient perspective. Methods: We conducted focus group sessions and semi-structured interviews of women treated for bladder cancer to identify patient priorities and concerns until reaching topic saturation. Transcripts were analyzed thematically. Results: Eight patients with muscle-invasive bladder cancer and six patients with non-muscle-invasive bladder cancer participated in two focus groups and seven interviews total. Three themes emerged as significantly affecting the care experience: physical impacts, mental health and emotional wellbeing, and the patient-provider interaction. Each theme included patient-defined specific recommendations on approaches to optimizing the care experience for women with bladder cancer. Conclusions: Although most participants were satisfied with the quality of care they received, they identified several opportunities for improvement. These concerns centered around enhancing support for patients' physical and mental needs and strengthening the patient-provider interaction. Efforts to address these needs and reduce gender disparate outcomes via quality improvement initiatives are ongoing. Competing Interests: Amanda Vo, Mary Kate Keeter, and Emily Tuchman do not have conflicts of interest related to this work to declare. Alicia Morgans has the following honoraria for advisory board activities to report: Janssen, Sanofi, Astellas, AstraZeneca, Bayer, Dendreon, Myovant, Advanced Accelerator Applications, and Clovis. In addition, Alicia Morgans has the following research collaborations to report: Bayer, Seattle Genetics, Astellas, Sanofi, Dendreon. Joshua Meeks does consulting work for Merck, AstraZeneca, Ferring, Cold Genesys, Janssen, Nucleix, and Foundation Medicine. He is funded for research by Abbvie, Tesaro, Epizyme, Prostate Cancer Foundation, Hope Foundation, VHA, NIH, and DoD. He has received education funding for lectures from AUA, OncLive, University North Carolina, and ASCO. Lastly, Dr. Meeks has clinical trials with SWOG, Genentech, Merck, and AstraZeneca. (© 2021 – The authors. Published by IOS Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu